GVS SpA Reports 2025 Earnings Highlights
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 31 2026
0mins
Should l Buy HAE?
Source: Yahoo Finance
- Sales Growth: GVS SpA achieved sales of EUR 425 million in 2025, reflecting a 2% increase compared to 2024 when excluding foreign exchange impacts, indicating stable market performance despite external challenges.
- Adjusted EBITDA Improvement: The adjusted EBITDA reached EUR 107 million, up 3% from 2024, with a margin increase from 24.3% to 25.2%, showcasing the company's ongoing improvements in cost control and operational efficiency.
- Strong Performance in Safety Division: The Safety division recorded nearly 12% growth, demonstrating robust demand in this segment, which is expected to support future revenue growth for the company.
- Negative Impact Factors: The Energy & Mobility division saw a 7.5% decline in sales, along with a EUR 10 million negative impact from the US Dialysis business, indicating challenges in certain areas that require strategic responses to market fluctuations.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy HAE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on HAE
Wall Street analysts forecast HAE stock price to rise
8 Analyst Rating
4 Buy
4 Hold
0 Sell
Moderate Buy
Current: 54.370
Low
74.00
Averages
88.86
High
99.00
Current: 54.370
Low
74.00
Averages
88.86
High
99.00
About HAE
Haemonetics Corporation is a medical technology company. Its solutions address critical medical needs, which includes a suite of hospital technologies designed to advance standards of care and help enhance outcomes for patients; end-to-end plasma collection technologies to optimize operations for plasma centers, and products to enable blood centers to collect in-demand blood components. Its Plasma segment includes plasma collection devices and disposables, donor management software and supporting software solutions. Its Blood Center segment manufactures and provides customers with its full line of apheresis solutions for automated blood collection. Its Hospital segment consists of Interventional Technologies, which includes Vascular Closure, Sensor Guided Technologies and Esophageal Protection products, and Blood Management Technologies (Hemostasis Management, Cell Salvage and Transfusion Management products). It also offers solutions for structural heart and endovascular procedures.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Haemonetics Q4 Fiscal 2026 Earnings Call Insights
- Revenue Growth: Haemonetics reported fourth-quarter revenue of $346 million for fiscal 2026, reflecting a 5% increase year-over-year and a 9% organic growth, driven by a robust performance in blood management technologies that saw a 21% revenue increase in the quarter, indicating sustained market demand.
- Margin Changes: The adjusted gross margin for Q4 was 59.7%, down 50 basis points year-over-year, while the full-year gross margin expanded to 60.3%, highlighting the company's efforts in cost control and profitability despite tariff pressures impacting margins.
- Cash Flow Performance: The company generated $45 million in free cash flow in Q4, bringing the total for the year to $210 million with a conversion ratio of 89%, demonstrating significant improvement in cash generation capabilities that will support future investments and shareholder returns.
- Future Outlook: Management expects revenue growth for fiscal 2027 to be between 4% and 7%, with adjusted operating margins projected to improve by 50 to 100 basis points year-over-year, reflecting confidence in future performance despite challenges from tariffs and market fluctuations.
See More
HAEMONETICS CORP - FISCAL 2027 REVENUE GUIDANCE REVEALS 4% - 7% GROWTH - SEC FILING
Fiscal Guidance for 2027: The report outlines the fiscal guidance for the year 2027, indicating a projected revenue growth of 4% to 7%.
Sector Filings: The document highlights the importance of sector filings in relation to the fiscal guidance and revenue projections.
See More
Haemonetics Q4 Earnings Beat Expectations
- Earnings Beat: Haemonetics reported a Q4 non-GAAP EPS of $1.29, exceeding expectations by $0.02, indicating the company's stable profitability and growth potential.
- Revenue Growth: The company achieved Q4 revenue of $346 million, a 4.5% year-over-year increase, surpassing analyst expectations by $9.14 million, reflecting its competitive position and sustained product demand in the market.
- Positive Market Reaction: The earnings beat has bolstered investor confidence in Haemonetics, which is expected to drive the stock price up in the short term, enhancing its market valuation.
- Optimistic Outlook: With ongoing product line optimization and strategic market initiatives, Haemonetics is poised for steady growth in the coming quarters, further solidifying its leadership position in the medical device industry.
See More
Haemonetics Set to Announce Q4 Earnings on May 7
- Earnings Announcement: Haemonetics (HAE) is set to release its Q4 earnings on May 7 before market open, with a consensus EPS estimate of $1.27, reflecting a 2.4% year-over-year growth, indicating stable profitability.
- Revenue Expectations: The consensus revenue estimate stands at $336.86 million, up 1.8% year-over-year, suggesting sustained demand in the blood management and plasma markets, which may further enhance its market share.
- Historical Performance: Over the past two years, HAE has exceeded EPS estimates 100% of the time and revenue estimates 88% of the time, showcasing the company's reliability in financial forecasting and market confidence.
- Estimate Revision Dynamics: In the last three months, EPS estimates have seen 2 upward revisions and 9 downward revisions, while revenue estimates experienced 6 upward and 5 downward revisions, indicating market divergence and uncertainty regarding the company's future performance.
See More
Analysis of Poor Cash Flow Performance Companies
- Caleres Risk Analysis: Caleres (NYSE:CAL) has shown only 5.4% annual revenue growth over the past five years, falling short of consumer discretionary sector standards, indicating management's ineffective investment decisions that have led to declining returns on capital, while its 8x net debt-to-EBITDA ratio suggests over-leverage, increasing the risk of shareholder dilution.
- Smith & Wesson Sales Decline: Smith & Wesson (NASDAQ:SWBI) has experienced a 12.2% annual sales decline over the past five years, reflecting unfavorable consumer trends, and its lack of free cash flow limits opportunities for reinvestment, share repurchases, or capital distribution, with a forward P/E of 48.2 indicating potential overvaluation risks.
- Haemonetics Performance Concerns: Haemonetics (NYSE:HAE) has failed to meet organic revenue growth benchmarks over the past two years, suggesting a need for improvements in products, pricing, or go-to-market strategies, while its 6.6% return on invested capital reflects management's challenges in identifying attractive investment opportunities, trading at $59.71 with a forward P/E of 11.4.
- High-Quality Stock Recommendations: Despite the risks, there are still high-quality stocks worth watching, with StockStory's list of strong momentum stocks including companies like Nvidia and Exlservice, highlighting the best time to own great stocks is when the market is finally noticing them.
See More
Haemonetics Announces Study Results for VASCADE MVP XL System
- Clinical Study Results: Haemonetics' published study indicates that the VASCADE MVP®XL outperforms the VASCADE MVP in large-bore venous closure procedures, achieving higher success rates and zero bleeding complications, highlighting its potential in electrophysiology applications.
- FDA Label Expansion: In March 2026, the FDA approved the expanded labeling for the VASCADE MVP XL to include use with 10-14F inner diameter and up to 17F outer diameter sheaths, enhancing its applicability in market-leading technologies.
- Multicenter Trial Support: The FDA approval was supported by clinical evidence from the AMBULATE EXPAND trial, which evaluated the safety and effectiveness of technologies using 17F maximum outer diameter sheaths, demonstrating the clinical advantages of VASCADE MVP XL.
- Future Outlook: Haemonetics will present clinical data related to the VASCADE MVP XL system at the upcoming HRS 2026 conference, emphasizing its significance and application prospects in the rapidly evolving electrophysiology landscape.
See More
Haemonetics Q4 Fiscal 2026 Earnings Call Insights
- Revenue Growth: Haemonetics reported fourth-quarter revenue of $346 million for fiscal 2026, reflecting a 5% increase year-over-year and a 9% organic growth, driven by a robust performance in blood management technologies that saw a 21% revenue increase in the quarter, indicating sustained market demand.
- Margin Changes: The adjusted gross margin for Q4 was 59.7%, down 50 basis points year-over-year, while the full-year gross margin expanded to 60.3%, highlighting the company's efforts in cost control and profitability despite tariff pressures impacting margins.
- Cash Flow Performance: The company generated $45 million in free cash flow in Q4, bringing the total for the year to $210 million with a conversion ratio of 89%, demonstrating significant improvement in cash generation capabilities that will support future investments and shareholder returns.
- Future Outlook: Management expects revenue growth for fiscal 2027 to be between 4% and 7%, with adjusted operating margins projected to improve by 50 to 100 basis points year-over-year, reflecting confidence in future performance despite challenges from tariffs and market fluctuations.
See More
HAEMONETICS CORP - FISCAL 2027 REVENUE GUIDANCE REVEALS 4% - 7% GROWTH - SEC FILING
Fiscal Guidance for 2027: The report outlines the fiscal guidance for the year 2027, indicating a projected revenue growth of 4% to 7%.
Sector Filings: The document highlights the importance of sector filings in relation to the fiscal guidance and revenue projections.
See More
Haemonetics Q4 Earnings Beat Expectations
- Earnings Beat: Haemonetics reported a Q4 non-GAAP EPS of $1.29, exceeding expectations by $0.02, indicating the company's stable profitability and growth potential.
- Revenue Growth: The company achieved Q4 revenue of $346 million, a 4.5% year-over-year increase, surpassing analyst expectations by $9.14 million, reflecting its competitive position and sustained product demand in the market.
- Positive Market Reaction: The earnings beat has bolstered investor confidence in Haemonetics, which is expected to drive the stock price up in the short term, enhancing its market valuation.
- Optimistic Outlook: With ongoing product line optimization and strategic market initiatives, Haemonetics is poised for steady growth in the coming quarters, further solidifying its leadership position in the medical device industry.
See More
Haemonetics Set to Announce Q4 Earnings on May 7
- Earnings Announcement: Haemonetics (HAE) is set to release its Q4 earnings on May 7 before market open, with a consensus EPS estimate of $1.27, reflecting a 2.4% year-over-year growth, indicating stable profitability.
- Revenue Expectations: The consensus revenue estimate stands at $336.86 million, up 1.8% year-over-year, suggesting sustained demand in the blood management and plasma markets, which may further enhance its market share.
- Historical Performance: Over the past two years, HAE has exceeded EPS estimates 100% of the time and revenue estimates 88% of the time, showcasing the company's reliability in financial forecasting and market confidence.
- Estimate Revision Dynamics: In the last three months, EPS estimates have seen 2 upward revisions and 9 downward revisions, while revenue estimates experienced 6 upward and 5 downward revisions, indicating market divergence and uncertainty regarding the company's future performance.
See More
Analysis of Poor Cash Flow Performance Companies
- Caleres Risk Analysis: Caleres (NYSE:CAL) has shown only 5.4% annual revenue growth over the past five years, falling short of consumer discretionary sector standards, indicating management's ineffective investment decisions that have led to declining returns on capital, while its 8x net debt-to-EBITDA ratio suggests over-leverage, increasing the risk of shareholder dilution.
- Smith & Wesson Sales Decline: Smith & Wesson (NASDAQ:SWBI) has experienced a 12.2% annual sales decline over the past five years, reflecting unfavorable consumer trends, and its lack of free cash flow limits opportunities for reinvestment, share repurchases, or capital distribution, with a forward P/E of 48.2 indicating potential overvaluation risks.
- Haemonetics Performance Concerns: Haemonetics (NYSE:HAE) has failed to meet organic revenue growth benchmarks over the past two years, suggesting a need for improvements in products, pricing, or go-to-market strategies, while its 6.6% return on invested capital reflects management's challenges in identifying attractive investment opportunities, trading at $59.71 with a forward P/E of 11.4.
- High-Quality Stock Recommendations: Despite the risks, there are still high-quality stocks worth watching, with StockStory's list of strong momentum stocks including companies like Nvidia and Exlservice, highlighting the best time to own great stocks is when the market is finally noticing them.
See More
Haemonetics Announces Study Results for VASCADE MVP XL System
- Clinical Study Results: Haemonetics' published study indicates that the VASCADE MVP®XL outperforms the VASCADE MVP in large-bore venous closure procedures, achieving higher success rates and zero bleeding complications, highlighting its potential in electrophysiology applications.
- FDA Label Expansion: In March 2026, the FDA approved the expanded labeling for the VASCADE MVP XL to include use with 10-14F inner diameter and up to 17F outer diameter sheaths, enhancing its applicability in market-leading technologies.
- Multicenter Trial Support: The FDA approval was supported by clinical evidence from the AMBULATE EXPAND trial, which evaluated the safety and effectiveness of technologies using 17F maximum outer diameter sheaths, demonstrating the clinical advantages of VASCADE MVP XL.
- Future Outlook: Haemonetics will present clinical data related to the VASCADE MVP XL system at the upcoming HRS 2026 conference, emphasizing its significance and application prospects in the rapidly evolving electrophysiology landscape.
See More
